Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (82)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rakshi, J. S.
Right arrow Articles by Brooks, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rakshi, J. S.
Right arrow Articles by Brooks, D. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 122, No. 9, 1637-1650, September 1999
© 1999 Oxford University Press

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study

J. S. Rakshi1, T. Uema1, K. Ito1,4, D. L. Bailey1, P. K. Morrish1, J. Ashburner2, A. Dagher1, I. H. Jenkins1, K. J. Friston2 and D. J. Brooks1,3

1 MRC Cyclotron Unit, Hammersmith Hospital, 2 The Wellcome Department of Cognitive Neurology and 3 Department of Clinical Neurology, Institute of Neurology, London, UK and 4 Department of Biofunctional Research, National Institute for Longevity Sciences, Obu, Japan

Correspondence to: Dr James S. Rakshi, MRC Cyclotron Unit, Hammersmith Hospital, Du Cane Rd, London W12 ONN, UK E-mail: james{at}wren.rpms.ac.uk

We have studied focal changes in dopaminergic function throughout the brain volume in early and advanced Parkinson's disease by applying statistical parametric mapping (SPM) to 3D [18F]dopa-PET. Data from seven early hemi-Parkinson's disease and seven advanced bilateral Parkinson's disease patients were compared with that from 12 normal controls. Parametric images of [18F]dopa influx rate constant (Kio) were generated for each subject from dynamic 3D [18F]dopa datasets and transformed into standard stereotactic space. Significant changes in mean voxel [18F]dopa Kio values between the normal control group and each Parkinson's disease group were localized with SPM. Conventional region of interest analysis was also applied to comparable regions on the untransformed image datasets. In early left hemi-Parkinson's disease, significant extrastriatal increases in [18F]dopa Kio were observed in the left anterior cingulate gyrus and the dorsal midbrain region (P < 0.05, corrected) along with decreases in striatal [18F]dopa Kio. In advanced Parkinson's disease, significant extrastriatal decreases in [18F]dopa Kio were observed in the ventral and dorsal midbrain regions (P < 0.05, corrected). No significant changes in [18F]dopa Kio were observed in the anterior cingulate region. In a direct comparison between the early and late Parkinson's disease groups, we observed relative [18F]dopa Kio reductions in ventral and dorsal midbrain, and dorsal pontine regions along with striatal [18F]dopa Kio reductions. Similiar results were found with a region of interest approach, on non-transformed data, except for the focal midbrain [18F]dopa Kio increase seen in early Parkinson's disease. In conclusion, using SPM with [18F]dopa-PET, we have objectively localized changes in extrastriatal, pre-synaptic dopaminergic function in Parkinson's disease. The significance of the increased dopaminergic activity of anterior cingulate in early Parkinson's disease remains unclear, but may be compensatory. The [18F]dopa signal in dorsal midbrain and pontine regions suggests that [18F]dopa is taken up by serotonergic and noradrenergic neurons which also degenerate in advanced Parkinson's disease. This suggests, therefore, that Parkinson's disease is a monoaminergic neurodegenerative disorder.

Parkinson's disease; 3D [18F]dopa; focal changes; extrastriatal; progression

AADC = aromatic amino acid decarboxylase activity; COMT = catechol-O-methyl transferase; Kio = influx rate constant; MTGA = multiple time graphical analysis; rCBF = regional cerebral blood flow; SPM = statistical parametric mapping; UPDRS = Unified Parkinson's Disease Rating Scale


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BrainHome page
P. Marklund, A. Larsson, E. Elgh, J. Linder, K. A. Riklund, L. Forsgren, and L. Nyberg
Temporal dynamics of basal ganglia under-recruitment in Parkinson's disease: transient caudate abnormalities during updating of working memory
Brain, February 1, 2009; 132(2): 336 - 346.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Argyelan, M. Carbon, M.-F. Ghilardi, A. Feigin, P. Mattis, C. Tang, V. Dhawan, and D. Eidelberg
Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning
J. Neurosci., October 15, 2008; 28(42): 10687 - 10695.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
J. B. Rowe, L. Hughes, B. C. P. Ghosh, D. Eckstein, C. H. Williams-Gray, S. Fallon, R. A. Barker, and A. M. Owen
Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition
Brain, August 1, 2008; 131(8): 2094 - 2105.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
N. Sawamoto, P. Piccini, G. Hotton, N. Pavese, K. Thielemans, and D. J. Brooks
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease
Brain, May 1, 2008; 131(5): 1294 - 1302.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. Hirano, K. Asanuma, Y. Ma, C. Tang, A. Feigin, V. Dhawan, M. Carbon, and D. Eidelberg
Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease
J. Neurosci., April 16, 2008; 28(16): 4201 - 4209.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. H. Williams-Gray, A. Hampshire, R. A. Barker, and A. M. Owen
Attentional control in Parkinson's disease is dependent on COMT val158met genotype
Brain, February 1, 2008; 131(2): 397 - 408.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
C. H. Williams-Gray, A. Hampshire, T. W. Robbins, A. M. Owen, and R. A. Barker
Catechol O-Methyltransferase val158met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease
J. Neurosci., May 2, 2007; 27(18): 4832 - 4838.
[Abstract] [Full Text] [PDF]


Home page
Cereb CortexHome page
A. Vallesi, T. Shallice, and V. Walsh
Role of the Prefrontal Cortex in the Foreperiod Effect: TMS Evidence for Dual Mechanisms in Temporal Preparation
Cereb Cortex, February 1, 2007; 17(2): 466 - 474.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Van Laere, C. Casteels, L. De Ceuninck, B. Vanbilloen, A. Maes, L. Mortelmans, W. Vandenberghe, A. Verbruggen, and R. Dom
Dual-Tracer Dopamine Transporter and Perfusion SPECT in Differential Diagnosis of Parkinsonism Using Template-Based Discriminant Analysis
J. Nucl. Med., March 1, 2006; 47(3): 384 - 392.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P. Piccini, N. Pavese, P. Hagell, J. Reimer, A. Bjorklund, W. H. Oertel, N. P. Quinn, D. J. Brooks, and O. Lindvall
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease
Brain, December 1, 2005; 128(12): 2977 - 2986.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
X.-B. Pan, T. G. Wright, F. J. Leong, R. A. McLaughlin, J. M. Declerck, and D. H.S. Silverman
Improving Influx Constant and Ratio Estimation in FDOPA Brain PET Analysis for Parkinson's Disease
J. Nucl. Med., October 1, 2005; 46(10): 1737 - 1744.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A L Cheesman, R A Barker, S J G Lewis, T W Robbins, A M Owen, and D J Brooks
Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1204 - 1210.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. Scherfler, K. Seppi, E. Donnemiller, G. Goebel, C. Brenneis, I. Virgolini, G. K. Wenning, and W. Poewe
Voxel-wise analysis of [123I]{beta}-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease
Brain, July 1, 2005; 128(7): 1605 - 1612.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P. Remy, M. Doder, A. Lees, N. Turjanski, and D. Brooks
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
Brain, June 1, 2005; 128(6): 1314 - 1322.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
V. Bouilleret, F. Semah, A. Biraben, D. Taussig, F. Chassoux, A. Syrota, and M.-J. Ribeiro
Involvement of the Basal Ganglia in Refractory Epilepsy: An 18F-Fluoro-L-DOPA PET Study Using 2 Methods of Analysis
J. Nucl. Med., March 1, 2005; 46(3): 540 - 547.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. L. Whone, D. L. Bailey, P. Remy, N. Pavese, and D. J. Brooks
A Technique for Standardized Central Analysis of 6-18F-Fluoro-L-DOPA PET Data from a Multicenter Study
J. Nucl. Med., July 1, 2004; 45(7): 1135 - 1145.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. Scherfler, N. L. Khan, N. Pavese, L. Eunson, E. Graham, A. J. Lees, N. P. Quinn, N. W. Wood, D. J. Brooks, and P. P. Piccini
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism
Brain, June 1, 2004; 127(6): 1332 - 1342.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. E. Ahlskog
Slowing Parkinson's disease progression: Recent dopamine agonist trials
Neurology, February 11, 2003; 60(3): 381 - 389.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M Ghaemi, R Hilker, J Rudolf, J Sobesky, and W-D Heiss
Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging
J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 517 - 523.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
K. Ito, A. Nagano-Saito, T. Kato, Y. Arahata, A. Nakamura, Y. Kawasumi, K. Hatano, Y. Abe, T. Yamada, T. Kachi, et al.
Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study
Brain, June 1, 2002; 125(6): 1358 - 1365.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
D. J. Doudet
Radionuclide Imaging in Parkinson's Disease: Diagnosis, Treatment, and Disease Progression
Journal of Pharmacy Practice, August 1, 2001; 14(4): 341 - 350.
[Abstract] [PDF]


Home page
BrainHome page
V. Kaasinen, E. Nurmi, A. Bruck, O. Eskola, J. Bergman, O. Solin, and J. O. Rinne
Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex
Brain, June 1, 2001; 124(6): 1125 - 1130.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. T. M. Hu, S. J. White, A. H. Herlihy, K. R. Chaudhuri, J. V. Hajnal, and D. J. Brooks
A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease
Neurology, May 8, 2001; 56(9): 1195 - 1200.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
A. Dagher, A. M. Owen, H. Boecker, and D. J. Brooks
The role of the striatum and hippocampus in planning: A PET activation study in Parkinson's disease
Brain, May 1, 2001; 124(5): 1020 - 1032.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.